WO 95/25504 PCTIIJS95/03393
285803
~oi.sxgxaa axva asLxvsxx sysxsacs
The ability of drugs to be administered via the oral
route depends oa several factors. The drug must be soluble
is the gastrointestinal fluids in order for the drug to be
transported across biological membranes, or be suitable for
an active transport mechanism. Very small particulates (less
than 300 nanometers) can be absorbed through the lymphatic
system via the Peyer~s Patch system in the intestinal tract.
However, this mechanism is not capable of absorbing large
doses of drugs into the systemic circulation.
A problem arises for hard to dissolve drugs. In the
case of conventional drugs, some drugs are relatively
insoluble in gastrointestinal fluids. If the extent of
solubility is low, this may cause incomplete and/or erratic
absorption. If the rate of solubility is low, then
absorption will most probably be erratic on an intra-patient
and inter-patient basis. Peptide drugs can be water soluble,
and these are not ae problematic as insoluble peptides. Like
conventional drugs, insoluble peptides typically exhibit
incomplete or low extent of absorption and erratic absorption
or bioavailability.
-1-
a ~ ~s~o3
VI'O 95125504 PCTlUS95103393
The primary difficulty involved in delivering peptides
orally is their degradation by hydrolysis and proteolytic
enzymes. There are two basic approaches to eliminating this
difficulty. The first is an "enteric" coating that releases
the drug only in neutral to basic pH (usually pH 6-8), like
that found in the intestine, so that the peptide is not
exposed to gastric juices. However, this approach alone is
not sufficient to protect the peptide since proteolytic '
enzymes exist in the upper intestinal tract, and degradation
of the drug can still occur. The other approach is to
incorporate the peptide in a hydrophobic material so that
aqueous fluids cannot penetrate the system. It is important
to select a hydrophobic material that can erode or slowly
dissolve in the intestinal tract so that the drug is
released. In this way, the peptide is protected from
proteolytic enzymes. In addition, it is possible to combine
the two approaches. See, for example, With relation to the
enteric coating approach.
However, there are inherent difficulties with the
approaches outlined above. First, many drugs are released
too slowly from. hydrophobic systems. Also, some peptides
will partition into the hydrophobic phase so that they will
not be fully released from these systems. Thus, both the
rate and extent of drug release are crucial components of any
drug delivery system, and are even more important for many
peptide drugs.
In accordance with the present invention there is
provided a pharmaceutical composition comprising a
pharmaceutical agent incorporated into a phazmaceutical
carrier emulsion comprised of a hydrophobic material selected
from the group consisting of a long chain carboxylic acid,
long chain carboxylic acid ester, long chain carboxylic acid
-2-
2185803
-VI'O 95125503 PG°T/U595/03393
_- alcohol and mixtures thereof emulsified with a hydrophilic
material.
The composition is used for convenient delivery of
drugs. A wide range of active agents can be administered in
' the composition, including antibiotics, antimicrobials,
antineoplastics, antivirals, cardiovascular and renal agents,
immunosuppressive and immunostimulatory agents, and CNS
active agents, but it is of particular value for peptides.
Microemulsion, compared with normal (macro-) emulsions, form
easily, even spontaneously, without high energy input, and
scale-up easily. They are stable, with long shelf life, and,
being translucent, are easy to monitor spectroscopically.
They have low viscosity for easy transport and mixing. Drug
solubilization, protection against enzyme hydrolysis and,
therefore, oral bioavailability, particularly for peptides,
are enhanced.
In one embodiment, the hydrophobic material forms the
discontinuous phase and the hydrophilic material forms the
continuous phase in which the hydrophobic material is
emulsified (oil-in-water). The hydrophobic discontinuous
phase and the hydrophilic continuous phase can each
independently be solid, semisolid or liquid. The
pharmaceutical agent may be dispersed or incorporated into
the hydrophobic material, the hydrophilic material or in both
the hydrophobic and hydrophilic materials. Preferably the
carrier emulsion is a microemulsion.
In another embodiment, the hydrophobic material forms
the continuous phase and the hydrophilic material forms the
discontinuous phase in which the hydrophobic material is
emulsified(water-in-oil). The hydrophobic discontinuous
phase and hydrophilic continuous phase can each independently
' be solid, semisolid or liquid. The pharmaceutical agent may
-3-
CA 02185803 2004-12-O1
74872-168
be dispersed or incorporated into the hydrophobic material,
the hydrophilic material or in both the hydrophobic and
hydrophilic materials. Preferably the carrier emulsion is a
microemulsion. In this embodiment the invention provides a
pharmaceutical preparation comprising a water-in-oil
emulsion, preferably a microemulsion, containing an oil
phase (such as a long chain carboxylic acid or ester or
alcohol thereof), a surface active agent (such as poloxamer)
and an aqueous phase containing the drug. The advantage of
l0 using a water-in-oil microemulsion is that it has the
ability to dissolve relatively large amounts of polar
solutes in an~overall oily environment, creating an oral
delivery system for peptide and protein drug molecules.
In one aspect, the invention provides a
pharmaceutical composition, comprising: an emulsion with a
hydrophobic phase selected from the group consisting of
saturated or unsaturated C12 to C2z carboxylic acids, C1z to
C2z carboxylic acids esters, alcohols resulting from the
hydroxyl forms of C1~ to C22 carboxylic acids and combinations
thereof; an aqueous hydrophilic phase, wherein one of the
phases is a discontinuous phase and the other a continuous
phase; at least one surfactant for dispersing the
discontinuous phase in the continuous phase selected from
the group consisting of polyoxyethylene sorbate C8-CZa
carboxylic acid ester surfactants, sorbitan Ce-C22 carboxylic
acid ester surfactants, ethylene or propylene oxide block
copolymer surfactants, polyglycolyzed glyceride surfactants,
sorbitan esters of oleate, stearate, laurate or other CB-C2a
carboxylic acids, poloxamers, other sorbitan or sucrose
Ce-C22 carboxylic acid esters, mono and diglycerides, PEG
derivatives of caprylic/capric triglycerides and mixtures
thereof and combinations thereof;
4
i u.. i I. . ~I~n ~. i i i
CA 02185803 2004-12-O1
74872-168
and a pharmaceutical agent dissolved in said discontinuous
phase.
Figure 1 shows the results of the experiments
described in Example 8.
Figure 2 shows the results of the experiments
described in Example 9.
Figure 3 shows the results of the experiments
described in Example 10.
Figure 4 shows the results of the experiments
described in Example 11.
Figure 5 shows the results of the experiments
described in Example 12.
An emulsion is a dispersed system containing at
least two immiscible liquid phases, a hydrophobic phase and
a hydrophilic phase. The emulsion comprises the dispersed
phase, the dispersion phase and an emulsifying agent or
surfactant agent, except when the hydrophobic material is a
"self-emulsifying" ester, whereby it is possible to produce
4a
-W 0 95125504 ~ ~ , ~ ' ' 1'' ~ ~ 218 5 8 0 3 PC,I,~S95I03393
_- an emulsion without a separate emulsifying agent. Usually
one of the two immiscible liquids is an oil while the other
is aqueous. Which phase becomes the dispersed phase depends
on the relative amounts of the two liquid phases and which
emulsifying agent is selected. Therefore, an emulsion in
Which the oil is dispersed as droplets throughout the aqueous
phase is called an oil-in-water (o/w) emulsion and vice
' versa. The term "colloidal" refers to emulsions in which the
dispersed phase is of very fine particles, usually less than
about 1 mm in size. A "microcolloid" is an emulsion wherein
the dispersed particles are usually about 100 um or less in
size. Cosurfactants are also common components of
microcolloids and are simply surfactants included in addition
to the primary surfactant.
A "microemulsion" is an optically isotropic and
thermodynamically or kinetically stable liquid emulsion.
Microemulsions are composed of an oily phase, an aqueous
phase, a surfactant and sometimes a cosurfactant. They are
ideal for oral drug delivery systems- since they are
homogeneous, thermodynamically stable, have uniform droplet
sizes of approximately 200 and are optically clear. A
water-in-oil microemulsion, in particular, has small aqueous
phase droplets, uniformly dispersed in a continuous oil
phase. Therefore, over a wide range of peptide solubilities
the peptide is protected from proteolytic enzymes that are
soluble in the digestive fluids. In general, the chemical
structure of peptides dictates that they be at least somewhat
if not mostly water soluble, and thus will be located inside
the water droplet or very near the surface of the droplet of
the water-in-oil microemulaion system. Thus, the outer oily
phase of the microemulsion will prohibit migration of
proteolytic enzymes through the delivery system. The outer
oily phase of the microemulsion is also able to incorporate
into the intestinal cell matrix, thus creating channels
-5-
wo 9s~assoa G A 218 5 8 0 3
PCTIUS95103393
(either para cellularly or transcellularly) through which the
peptide drug could pass.
Therefore it is important to select a hydrophobic
material that can erode or slowly dissolve in the intestine
or become incorporated into the intestinal cell matrix so
that the drug is released. in addition, it is possible to
combine the two approaches, for example, with relation to the
enteric coating approach.
The oil-in-water emulsions of the invention are
generally made by adding hot (70-80° C) hydrophobic phase
(smaller by weight) to hot (70-80° C) hydrophilic phase
(larger by weight) forcing inversion of the surface active
agent to form a disperse emulsion of unaggregated dispersed
phase particles. This produces an emulsion when-processed
under suitable shear. The drug is usually added with the
hydrophobic material when it is an organic molecule that is
poorly soluble in aqueous media. The drug is usually added
after the emulsion has been formed and allowed to cool when
it is a peptide. The drug in emulsion fozmulation is then
filled into a soft or hard gelatin capsule, tablet or other
oral dosage form.
In accordance with the present invention certain
hydrophobic materials, when emulsified in a continuous phase
of a hydrophilic material provide enhanced absorption
capabilities for oral delivery of peptide drugs and drugs
that are poorly soluble in aqueous media. In accordance with
the invention, these materials are selected from the group
consisting of long chain carboxylic acids, long chain
carboxylic acid esters, long chain carboxylic acid alcohols
and mixtures thereof.
-6-
n~ r1
-W O 95125504 ~ ~ ~ ~ ~ ~ ~ PCT/U595103393
-_ Further, certain materials, when combined in accordance
with the invention to form a water-in-oil microemulsion, give
enhanced absorption capabilities. These materials are an
oily phase, composed of long chain fatty acids or esters or
alcohols thereof, an aqueous phase composed primarily of
water, and a surface active agent, primarily of the non-ionic
block copolymer type, that are mixed together to form a
water-in-oil microemulsion.
The long chain carboxylic acids, generally contain from
4-36 carbon atoms and preferably contains at least 12 carbon
atoms, most preferably 12 to 22. in some cases this carbon
chain is fully saturated and unbranched, while others contain
one or more double bonds. They can have saturated,
unsaturated, branched or straight chain hydrocarbon chains.
A few contain 3-carbon rings or hydroxyl groups. The
compounds are not surface active. They are poorly soluble in
water and the longer the acid chain and the fewer the double
bonds, the lower the solubility in water. The carboxylic
acid group is polar and ionized at neutral pH. This accounts
for the slight solubility of short-chain acids in water.
Examples of such acids are those ranging from C,~ to C=,
with up to three unsaturated bonds (also branching).
Examples of saturated straight chain acids are n-dodecanoic
acid, n-tetradecanoic acid, n-hexadecanoic acid, caproic
acid, caprylic acid, capric acid, lauric acid, myristic acid,
palmitic acid, stearic acid, arachidic acid, behenic acid,
montanic acid and melissic acid. Also useful are unsaturated
monoolefinic straight chain monocarboxylic acids. Examples
of these are oleic acid, gadoleic acid and erucic acid. Also
useful are unsaturated (polyolefinic) straight chain
monocaboxyic acids. Examples of these are linoleic acid,
ricinoleic acid, linolenic acid, arachidonic acid and
CA 02185803 2004-12-O1
74872-168
behenolic acid. Useful branched acids include, for example,
diacetyl tartaric acid.
Bxamples of long chain carboxylic acid esters include,
but are not limited to, those fray the group of : glyceryl
monostearates; glyceryl monopalmitates; mixtures of,glyceryl
monostearate and glyceryl monopalmitate (Myvaplex"" 600,
Eastman Fine Chemical Company); glyceryl monoliuoleate;
glyceryl monooleate; mixtures of glycexyl mQnopalmitate,
glyceryl monostearate, glyceryl monooleate and glyceryl
monolinoleate (Myverol~l8-92, Bastman Fine Chemical Company):
glyceryl monolinolenate; glyceryl moaogadoleate; mixtures of
glyceryl monopalmitate, glyceryl monostearate, glyce~cyl .
monooleate, glyceryl monolinoleate, glyceryl monolinolenate
and glyceryl monogadoleate (Myverol~ 18-99, Eastman Fine
Chemical Company); acetylated glycerides such as distilled
acetylated monoglycerides (Myvacet'" 5-07, 7-07 and 9-45,
Eastman Fine Chemical ComQany); mixtures of propylene glycol
monoestere, distilled monoglycerides, sodium stearoyl
lactylate and silicon dioxide (Myvatex'" TL, 8astman Fine
Chemical Company); mixtures of propylene glycol monoesters,
distilled moaoglycerides, sodium stearoyl lactylate and
silicon dioxide (Myvate~""TL, Eastman Fine Chemical Company)
d-alpha tocopherol polyethylene glycol 1000 succinate
(vitamin 8 TPGB, Eastman Chemical Company); mixtures of mono-
and di-glyceride esters such as Atmul'~ (8umko Chemical
Division of Witco Chemical); calcium stearoyl lactylate;
ethoxylated mono- and di-glycerides; lactated mono- and di-
glycerides: lactylate carboxylic acid ester of glycerol and
propylene glycol; lactylic esters of long chain carboxylic
acids; polyglycerol esters of long chain carboxylic acids,
propylene glycol mono- and di-esters of long .chain carboxylic
acids; sodium stearoyl lactylate; sorbitan monostearate;
sorbitaa monooleate; other sorbitaa esters of long chain
carboxylic acids; succinylated monoglycerides; stearyl
-8-
- . v . . n li -~ . .la . , i n i
CA 02185803 2004-12-O1
74872-168
monoglyceryl citrate; stearyl heptanoate; cetyl esters of
waxes; stearyl octanoate; C,o-C,o cholesterol/lavosterol
esters; sad sucrose long chain carboxylic acid esters.
8xamples of the self-emulsifying long chain carboxylic
acid esters include those from the groups of stearates,
palmitates, ricinoleates, oleates, behenates, ricinoleaates,.
myristates, laurates, caprylates, and caproates.
The alcohols useful is the invention are exemplified by
the hydroxyl forms of the carboxylic acids exemplified above
and also stearyl alcohol.
Additives to the carboxylic acid/alcohol phase can be
used to create a solid at roan temperature. This addition
affords the opportunity to make better use of enteric
coatings. Examples of such additives are glycerol beheaate,
cetyl alcohol, stearic acid, sorbitaa ester derivatives such
as sorbitan stearate, sobitan isostearate, polyethylene
glycol 1000 to 6000.
The types of protective or sustained release coatings
that can be used include, but are not limited to,
ethylceiluloee, hydroxypropylmethylcellulose,
hydroxypropylcellulose, bydroxyethylcellulose and esters of
methacrylic and ethacrylic acid (Budragft~"RL, RS, sad NB
polymer products, R.olaa Pharma, Danostadt, Germany) . The
enteric protective materials or coatings can be, for example,
cellulose acetate pthalate, hydroxypr~opylmethylcellulose
pthalate, ethylvinylacetate pthalate, polyviaylacetate
pthalate sad esters of methacrylic and ,ethacrylic acid
(Budragit~" S, Budragitt"" L and Budragit'~ E30D, Ro~a Pharma,
Darmstadt, Ger.).
-9-
CA 02185803 2004-12-O1
74872-168
The composition or preparation of the invention can
further include a surfactant, or a mixture of taro or snore
surfactants. A surfactant is an ~amphiphilic molecule
consisting of a hydrophobic tail and a hydrophilic head.
These molecules possess distinct regions of both hydrophilic
and hydrophobic character. The hydrophobic tail .can be a
hydrocarbon or fluorocarbon chain of 8 to 18 carbon atoms.
They are long chain molecules such as, for example, soaps or
detergents. Surfactants accumulate at the hydrophilic/
hydrophobic Iwater/oil) interface and loner the surface
tension. Surface active agents or surfactants are long chain
molecules, such as soaps and detergents, which accumulate at
the hydrophilic/hydrophobic(water/oil) interface and lower
the surface tension at the interface. ~e effect of a
reduced surface tension is the stabilization of the
emulsions. This is because molecules with both polar and
non-polar groups become oriented such that the hydrocarbon
tail embeds itself into the hydrophobic phase and the
hydrophilic head protrudes into the hydrophilic phase. ~e
the hydrophobic caaposition or. other component of the
preparation includes a surface-active agent, such as a
surfactant, it is usually present in amounts of about 0.05
to 50.0 weight/weight of the hydrophobic coa~ositioa with a
preferred range of l.Ot to 3.0~ (w/w).. Preferred surfactants
include, for example, the Zl~reesi Ipolyoxyethyleae sorbate)
family of surfactants (ICI, Wilmington DB) , the Spars (sorbitan
long chain carboxylic acid esters) family of
surfactants(ICI), the Pluronic(ethyleae or propylene oxide
block copolyiaers) family of surfactants (8A8F, Parsippaay NJ) ,
the Labrasol~ Labrafil'" and Labrafac (each polyglycolysed
glycerides) families of surfactants(Gappe Fosse, St. Priest,
France), sorbitan esters of oleate, etearate, laurate or
other long chain carboxylic acids, poloxamers (polyethyleae-
polypropylene glycol block copolymers), other sorbitan or
sucrose long chain carboxylic acid esters, moano and
-10-
~WO 951255D.~ ~ ~~ 218 5 8 0 3 pCT~S95103393
diglycerides, PEG derivatives of caprylic/capric
triglycerides and mixtures thereof.
The drugs to be incorporated individually or as
combinations in the pharmaceutical preparations of the
invention are those having less than about 80% oral
bioavailability. The term ~~bioavailability" as used here
means the rate and extent of systemic absorption of a drug
from the oral route of administration.
In one aspect, the drug is a polypeptide, usually of
less than about 15 amino acids. Examples include
cyclosporin, angiotensin I, II and III, encephalins,
enkephalins and their analogs, ACTH, aatiinflammatory
peptides I, II, III, bradykinin, calcitonin, cholecystikinin
(CCK) fragments 26-33 and 30-33, pre/pro CCK (V-9-M), Q-
endorphin, dinorphin, leucokinin, leutinizing hormone
releasing hormone (LI3RH), neurokinins (e.g. neurokinin A),
somatostatia, substance P, thyroid releasing hormone (TRH),
vasopressin, fibrinogen receptor antagonists (arginine-
glycine-aspartic acid containing peptides) which are platelet
aggregation inhibitors, growth hormone releasing peptides
(GHRP), insulin, LH-RH releasers and inhibitors, endothelins,
artial natreutetic factor, gastrin, cytoprotectives, MSH
modulators, or elastase or growth factors and cytokines,
renin inhibitors, anii HIV protease inhibitors.
In another aspect, the drug is as organic molecule that
is poorly soluble in aqueous media. These organic molecules
usually have a molecular weight (m. w.) of less than about
1,000 daltons, and usually less than about 600 daltons.
8xamples include cabamazepine, griseofulvin, angioteasin
converting enzyme inhibitors, flutamide, nifedipine,
acyclovir, gancyclovir, indomethacin, naproxen, estrogens,
-11-
W O 95!25504 ~ ~ ? ~ ~ ~ ~ 0 3
PC.°TIUS95f03393
testosterones, steroids, phenytoin, ergotamines and
cannabinoids.
Preferred drugs that meet these criteria include, but
are not limited to, angiotensin I, II and III, ACTH, anti-
inflammatory peptides 1, 2 and 3, bradykinin, cyclosporin,
calcitonin, CCK fragments 26-33 and 30-33, Pre- pro-CCK (V-9-
M), beta-endorphin, dynorphin, leucokinin, LHRIi, neurokinin
A, somatostatin, substance P, TRFI, vasopressin, enkephalin
analogues, ebiratide, galanin, and growth hormone releasing
hormone.
In accordance with the invention, drugs are incorporated
into the microemulsions by admixture using conventional
mixing devices and homogenizera used for semi-solid ointments
and lotions, with agitation at speeds common to emulsified
products such as creams and emulsions. Sxamplea of common
equipment employed ase propeller or turbine mixers,
homogenizers, colloid mills, ultrasonic mixers and
microfluidizers. 8xamples of such brand name mixing
equipment are Lee Kettle, Gaulin mixer and Stephan. The
shear of the agitation should be sufficient to form a stable
dispersion, but not too great to cause degradation of the
drug. The shear forces will form aggregates that have
diameters ranging from 100 - 500 angstroms. Suitable
homogenizers are available from Micromedics, Inc., Silverson,
and APV Crepaco, Arde Barinco. Stephen and Fryma mixers can
also be employed with suitable vacuum to prevent formation of
bubbles. Monitoring and evaluation of pH, viscosity,
specific gravity and aggregate sizes are necessary.
Using these devices, the mixture of drug in the
hydrophobic material (in the oil-in-water embodiment) is
formed into particles, e.g. beads or spheres, by spray-
congealing or ~~prilling~. This process uses a spray nozzle
-12-
. ~. ~7 218_5803
~WO 95/25504 PCfIUS95/03393
which atomizes the material in a cooling tower or chamber.
As the material is sprayed, surface tension causes a uniform
spherical bead to be formed. As the bead falls through the
cooling chamber, it hardens into a stable, intact sphere.
' The particles generally have a particle size of from 0.5
microns to 100 microns. It is preferred to reduce the size
' of the sphere as much as possible, most preferably below 10
microns. Optionally, the particles are coated with a
sustained-release coating and/or an enteric coating to modify
the rate of drug release from the particles.
The particles can be incorporated into hard gelatin
capsules, either with additional excipients, or alone.
Typical excipients to be added to a capsule formulation
include, but are not limited to: fillers such as
microcrystalline cellulose, soy polysaccharides, calcium
phosphate dehydrate, calcium sulfate, lactose, sucrose,
sorbitol, or any other inert filler. Ia addition, there can
be flow aids such as fumed silicon dioxide, silica gel,
magnesium stearate, calcium stearate or any other material
imparting flow to powders. Because of their hydrophobic
nature, the particles should not need a lubricant,~but one
can be added if necessary by using polyethylene glycol,
leucine, glyceryl behenate, magnesium stearate or calcium
stearate. '
The particles may also be incorporated into a tablet, in
particular by incorporation into a tablet matrix, which
rapidly disperses the particles after ingestion. In order to
incorporate these particles into such a tablet, a
filler/binder must be added to a tablet that can accept the
particles, but will not allow their destruction during the
tableting process. Materials that are suitable for this
purpose include, but are not limited to, microcrystalline
-13-
.!." . .
CA 02185803 2004-12-O1
74872-lb8
,r
cellulose (Avicel), soy polysaccharide (8mcosoy), pre-
gelatinized starches (STARCH 1500, National 1551), and
polyethylene glycols (Carbowax). The materials should be
present is the range of 5-75~ (w/w), with a preferred range
of 25-50~ (w/w) .
In addition, disintegrants are added in order to
disperse the particles once the tablet is ingested. suitable
disintegrants include, but are not limited to: cross-linked
,~
sodium carboxyunethyl cellulose (Ac-Di-Sol), sodium starch
glycolate (Bxplotab~; Primojel), aad cross-linked
polyvinylpolypyrrolidoae (Plasdone-XL). Theee materials
should be preseat in the range of 3-15~ (w/w), with a
preferred range of 5-10~ (w/w) .
Lubricaats are also added to assure proper tableting,
and these can include, but are not limited to: magnesium
stearate, calcium stearate, stearic acid, polyethylene
glycol, leuciae, giyce~cyl behaaate, aad hydrogenated
vegetable oil. These lubricants should be preeeat in amounts
from 0.1-10~ (w/w) , with a preferred range of 0.3-3.0~ (w/w) .
Tablets are forn~ed, for example, as follows . The
particles are introduced iato a blender along~with Avicel;"
disintegraats and lubricant, mixed for a set number of
minutes to provide a homogeneous blead which is then put is
the hopper of a tablet press with which tablets are
canpreseed.~ The compression force used is adequate to form
a tablet; however, not sufficient to fracture the beads or
coatings.
The capsule or tablet caa also be enteric coated.
Either the particles can be eateriC coated (Ph seasitive) and
released in the stomach or the capsule or tablet caa be
enteric coated (thereby releasing the particles is the
-14-
'v:e 2185803
WO95/2550.1 - PCT/US95/03393
intestine), in which case the particles need not be so
coated. To use only a sustained release coating on the
particle one would also need an enteric coated capsule or
tablet. There are three approaches here. First, there is
the uncoated hydrophobic particle in an enteric coated
capsule. Second, there is the sustained release coated
particle within an enteric coated capsule or tablet. Third,
there is the enteric coated particle enclosed within a
regular soft gelatin capsule or uncoated tablet.
The capsule may be further processed to provide gastric
protection by enterically coating the capsule. When the
contents of the capsule are released into the
gastrointestinal milieu, it spontaneously forms a
microcolliodal emulsion With the gastrointestinal fluid. The
gastrointestinal fluid acting as the aqueous phase.
Microemulsions are generally formed by adding the
aqueous phase, oily phase, and surfactant to a suitable
vessel and mixing. If any of the ingredient is a solid, it
should be added to a liquid phase in which it is soluble and
heated to dissolve. For example, if the surfactant is a
solid, and it is soluble in the oily phase, then it should be
dissolved completely, then followed with aqueous phase, etc.
On the other hand, if the surfactant is soluble in the
aqueous phase, then it should first be added to the aqueous
phase, dissolved completely, followed by the oily phase.
Appropriate alixing devices as mentioned above can be employed
for this purpose.
The preparation of an oil-in-water emulsion based
system, requires that the drug be diapered into the
hydrophobic material as described above, With the aqueous
phase being added in the presence of surfactant or self-
emulsifying hydrophobic long chain carboxylic acid ester.
-15-
- ' ~ . n~e 'I'-~..~Ln. 'i '
CA 02185803 2004-12-O1
74872-168
This procedure under suitable shear forms a microemulsion.
This emulsion is then filled into a soft or hard gelatin
capsule. The capsule may be further processed to provide
gastric protection by enterically coating the capsule.
Examples 1-7 describe forn~ulatioas that illustrate the
oil-in-water embodiment of the invention.
Phase Ingredients 8W/W
E Carbamazepine 5
H Glyceryl Monostearate 5-60
A Polysorbate 80 5
A Oleic Acid a-10
A Water q. s . to 100
The ingredients of each phase . are heated
separately to 70-80° C. Phase H is added to phase A while
mixing in an appropriate mixing device. The. mixture ie then
cooled to room temperature. The resultant emulsion is ready
to be incorporated into any suitable oral delivery dosage
form.
Phase Ingredients 8W/W
H Cyclosporiae 5
B Medium Chain Mono and Digiyceridee 19
A Polysorbate 80 5
B Oleyl Alcohol Z-l0
A Water q, s . to
100
The procedure is the same as that described fa Example 1.
-16-
. i i r.. i li .n , .Ln . , i n i
CA 02185803 2004-12-O1
74872-168
w
Phase Ingredients ~W/W
H AC8 Inhibitor 5 '
A Peg-25 Glyceryl Trioleate 30-60
H Oleyl Alcohol 2-10
A Water c~.s. to 100
The procedure is the 'same as that described in 8xan~ple 1.
Phase Ingredients ~W/W
samtoatatin 5
H Medium chain Mon o aad Dfglycerides 17
A Polysorbate 80 5
A Oleic Acid 2-10
A Water g.s. to 100
The procedure is the same as that described in Example i.
Phase Ingredient ~W/W
A Bnlcephalia 5
H Oleyl alcohol 14
C Sorbitaa Monooleate i4
D Polysorbate 80 14
s water q.s. ioo
Phase A aad H are mixed together, then C through B are added
in aay order pith stirring.
-17-
CA2185803
WO 95125504 PCTIUS95/03393
&XAMPLB 6
Phase Ingredient %W/W
A TRH
B d-Alphatocopheryl Polyethylene
glycol 1000 succinate 10
C d-alpha Tocophenol acetate 3
D Oleyl alcohol 2-10
B Water q.s. lODO
Ingredients B and C are heated to >40 C and mixed.
Ingredient A is then added. ingredient D
is then added to
the above and the resultant mixture is then added to
ingredient S, which is at -. 70-80C. This is then mixed
while cooling.
$~PLS 7
Phase Ingredient %W/w
A 8biratide
B Acetylated monoglycerides 10
C Dioctyl sodium sulfosyccinate 10
D Apricot Kernal oil 10
Water q.s. 100
Phase A is dissolved into D, then the other ingredients are
added with gentle stirring.
8xamples 8-12 describe formulations that illustrate the
water-in-oil embodiment of the invention and demonstrate ~n
vitro delivery enhancement .across Caco-2 cells using the
model peptide DAGO enkephalin.
Prevarataou of Caco 2 Cella
An in vitro model of intestinal epithelium, the Caco-2
human colon carcinoma cell line is used as the preliminary
assay system. These cells differentiate in culture to form
a confluent monolayer With the barrier properties of normal
-18-
285803
WO9512550.~ ' '' ~ PCTIUS95103393
intestinal epithelium. Cells are grown on permeable
membranes in a transport system with discrete, accessible
liminal and basil compartments.
The time course of differentiation, barrier formation,
and active transport of glucose has been determined. Cells
have been found to fbrm brush borders and tight junctions
between cells as demonstrated by electron microscopy, enzyme
assays, and reversible opening of calcium dependent junctions
by chelation. Transport of labeled peptides is measured from
luminal to basal compartments with time. Microemulsions are
compounded using physiologic buffers vs. the aqueous phase
and applied to the luminal surface of the cell monolayer.
Appearance of peptides is quantified and percent transport
per hour per square centimeter calculated and compared to
buffer alone.
~nQredients
Poloxamer 124 2~_0
Linoleic acid 63.1
Aqueous phase g.g
General Procedure
Mix ingredients well using one of the above mentioned
appropriate mixing devices in a suitable container to form an
optically clear solution. Add 10 mM DAGO enkephalin and
apply solution to Caco-2 cells. The results are shown in
Figure 1.
-19-
WO 95J25504 ~ ~ ~ 1 ~ ~ ~ ~ PCT/U595103393
Examvle 9
Inaredieata
Poloxamer 124 ig
Oleyl alcohol 75.9
Aqueous phase 5.1
~eaeral Procedure
Mix ingredients well using one of the above mentioned
appropriate mixing devices in a suitable container to form an
optically clear solution. Add 10 mM DAGO enkephalin and
apply solution to Caco-2 cells. The results are shown in
Figure 2.
~~le 10
Insrredieata
Poloxamer 124 27.0
Oleic acid 63.1
Aqueous phase 9,9
Szeneral Procedure
Mix ingredients well using one of the above mentioned
appropriate mixing devices in a suitable container to form an
optically clear solution. Add 10 mM DAGO enkephalin and
apply solution to Caco-2 cells. The results are shown in
Figure 3.
8amflle 11
Iaaredieats
Poloxamer 124 27.0
Linoleic acid 61.7
Aqueous phase 9,9
Behenic acid 1.35
-20-
n . ~~. i L ....I:w . i~ i
CA 02185803 2004-12-O1
74872-168
General Procedure
Melt behenic acid is linoleic in a suitable container at 50-
80°C. Co01 t0 40°C, add remaining ingredients and mix well.
Add 10 mM DAGO enkepbalin and apply solution to Caco-Z cells.
This microemulsion is a solid at roan temperature. The
results are shown in Figure 4.
~camfll~ iZ
,~acred~eats ~
Poloxamer 105 27.0
Linoleic acid 63.1
Aqueous phase 9.9
General Procedure
Mix ingredients well using one of the above mentioned
appropriate mixing devices is a suitable container to form as
optically clear solution. Add 10 aaM D~AGO eakephalia and
apply solution to Caco-2 cells. The results are shown in
Figure 5.
8acamcle ~3_
8luronic L44/Fatty Acid or ~llcohol/8aalc'~
8icroemuliioa System for the Transport o! p~ptides
ACroii CaCO-Z C~11~
Microen:uleion system formulations containing Platonic
L44 as the surf actaat , Hank' s buf f er as the aqueous phase and
several possible oily phases: oleyi alcohol, oleic acid, and
linoleic acid were prepared.
The following materials were used as received to prepare
the formulations: Polysorbate ~ZO, 60 and 80 (Tweets Z0, 60,
and 80, ICI Surfactants, Wilmington D8)~ glyceryl
monooleate/propylene glycol mixture, (Arlacel'~ 186, ICI
Surfactants, Wilmington D8); glyceryl monooleate ~Alda MO;"
Lonza Specialty Chemicals, Fair Laws, NJ); sorbitan
-ai-
, u... i li .~ ~ .l", ~. i , i
CA 02185803 2004-12-O1
74872-168
monooleate (Crill~"4, Croda, Parsippany, NJ); oleyl alcohol
(Janssen Chemica, Geer, Belgium); and linoleic acid (Bmersol'"
315 Henkel).
Multiple formulations were exan~i.ned in as effort to
utilise the polysorbate surfactant class is a microemulsion
vehicle for peptide delivery. The three ICI surfactants
Tween'" 20, 60, and 80 were employed in solution .and
microemulsion systems with and without cosurfactants. The
following present the formulations prepared.
Microemulsion formulations, consisting of Tweea"" 80,
Arlacel~" 186; oleyl alcohol and distilled water and the
corresponding Emulsifier (4 parts Tweea'~80/1 part Arlacel'"
186) solutions in Hank's buffer were prepared. See Table 1.
T)1BL= i
Iagredieata 7Z~1(~C) 7ZBi (~) 9ZBZ ('~)B3 (t) B4 (~C)
Tweea'~80 28.6 4 8 12 16
Arlacel'~ 186 42 . 9 1 2 3 4
Distilled 25 95 90 85 80
Water
Formulations with a higher percent of Emulsifier (4
parts Tweeri 80/1 part Arlacel~i86) solutions is Hank's buffer
were also prepared See Table 2.
TIIBLS Z
=aQrediaats 1 Z 3 s
Tweeri 80 16 20 Z4 28
Arlacel'" 4 5 6
Hank's buffer 80. 75 70 65
-22-
w" ~ i~," F~ ~. ~~
CA 02185803 2004-12-O1
~4s~2-ZS8
The formulation for a waterless microemulsion system,
consisting of Tweer~" B0, Arlacel'" 186 and Oleyl alcohol was
also prepared. See Table 3..
TIIBLB 3
Ingredients ~ '
Tweeri .80 36.9
Arlacel'~ 186 36. 9
Oleyl alcohol a6.1
The formulations for l0~ solutions of Tweets a0, 60 and
80 in Haak~s buffer each at pH 3.5 and 6.5 - 7.0 were
prepared. In this case, the peptide incorporated for the is
vasopressin at 10 ~M. See Table 4.
TllBIS 4
Iagredieati F (~) D (~t) B (~) I (~) JIB? B (~)
Tween'" 2 0 10 - - 10 - -
Tween'~ 6 0 - 10 - - 10 -
TweeaT""'8 0 - - 10 - - -
Hank~s buffer 90 90 90 90 90 90
Ph 6.51 6.91 6.8a 3.54 3.4 3.59
The formulation for a waterless microemulsion system,
consisting of Tweeri a0, Arlacel'~186 and Oleyl alcohol. (Note
different surfactant from formula above) . See Table 5.
TlIHLi 5
tagrediants 7aA(~) 9aH1 9a8s (~) H3 (SCI 84 (i~)
(~f
Tween'" 80 a8 . 6 4 8 1a 16
Arlaceh" 186 4a . 9 1 a ~ 3 4
Distilled a5 95 90 85 80
Water
-a3-
~" i, .~ ,i." ~. ", ,
CA 02185803 2004-12-O1
74872-168
Tweeri ZO/Spari 20 microemulsion formulations containing
linoleic acid as the oily phase were also prepared. See
Table 6.
TABLS 6
=agredieats 61~ 68 6C 6D 6E
Tween'"20 38.3 42.8 26.3 29 47.5
'~2~0 9.6 4.8 2.9 -
Linoleic Acid 47.8 47.5 68.1 67.6 47.5
Oleic Acid - - - -
Ole 1 Alcohol - - - - -
iiank' s buf 4 . 6 5 .1 3 3 . 6 5 . 2
f er
Tweeri 20/Spaii ZO microemulsion formulations coatainiag
either linoleic acid, oleic acid or oleyl alcohol were.aleo
prepared. See Table 7. ~ .
TAHi.E 7
:eas.dsssa ss sc sa ss aa~us sac ssous as
s.
aw.~"aoas. aa. a as aT. as.as, as.s as aT.s ar.s
.
a s a s ~ s
~.
a so s.s a.s a.s s.sa.a s.~ s.~
tsnel.ieaT. a~. ss. sT.s aT.
held s i t
0leia - . _ _ . aT.aT. fl.i ~T.aT.i
l~eid 1 i i
01.y1 _ _ . . . al.T
Aleohol
a.s :.i a a.s s.a a.ss.i a a.ss.a s.s
~tc.~
Three additional microemulsion formulations were also
prepared. See Tabie 8.
T118LS 8
Iagredieati 11(x) 8(~C) Ct~)
Pluronic'~L44 26.8 - -
-24-
i r a.... ~rli,r~~,l..nr~ilri
CA 02185803 2004-12-O1
74872-lb8
Labrasol'~ - 38.1 -
Labrafac CM-10 - 9.5 -
T~eeri 20 - - 42.8
S '~20. - - 4.76
Linoleic Acid 63.2 47.6 47:6
Hank's buffer 9.9 4.76 4.96
Further formulation efforts with Tween""20 led to a
microemulsion in which Span20 ie the cosurfactaat. Spau'~ZO,
or sorbitan monolaurate, acts as an ideal cosurfactaat.. The
oily phase of the new microemulsion systems has also been
changed to linoleic acid or oleic acid, rhich are lea to
promote peptide transport in other vehicles. Hank'a buffer
is the aqueous phase and linoleic acid, oleic acid or.oleyl
alcohol are the oily phases.
)~Kamola 14
Polysorbate Surfactant Systems and l~icro~ulsions
is Oral peptide Delivery.
The primary research initiative has bees to screen and
identify systems that increase peptide transport across Caco-
2 monolayers. One such syetan explored contains the
surfactant Pluronic~ L44. Several microeiaulsion systems
fozmulatione have been developed using this surfactant . This
example summarizes these syotems.
The following materials were used as received to prepare
the fonaulations: Pluronic'~L44 IHASF, Parsippaay, NJ); oleyl
Alcohol (Janasen Chemica, Geer, Belgium) ; oleic acid IBmersol'~
221, Henkel, Emery Group, Cincinaeti, O8); liaoleic acid
(Bmersol'" 315, Henkel, Emery Group, Cincinnati, OH); and
Hanks buffer (Ceilgro;' Mediatech).
-as-
»... ~ n ,. .i"".
CA 02185803 2004-12-O1
~4s~a-zss
The following tables list fonaulations prepared for use
in transport experiments. The tables give detailed
inforn~ation on the ingredients, amounts and pH, if
appropriate.
TaBLS 9
Percent Pluroaic h1~1 is Saalc~ s Hulfer
Formulation
G 8 I
Ingredient 8 8 8 8
Pluronic L44 0 7.5 15 30.0
Hank s 100 92.5 85.0 70.0
buf f er
T118h8 10
Formulation o! Pluroaic Ilicroemuliions
lormulatioa
D
Ingredients 8 8
Pluronic'"L44 26.8 30
Ole 1 alcohol 62.5 70
Hanks 10.7 0
T118L8 11
~icroamulsioas Containing Pluroaic L88. Oleyi 111cohol.
Haah~s Hufler and Solutioaa o! Plus~onic !68 and li08
patio
piuronic
L4~ to
losmulations Oleyl
711cohol
Iagredisats 11 8
Pluronic~"" 27 28 . 3 3
L44
ole 1 alcohol 63.1 66 7'
-2s-
CA 02185803 2004-12-O1
74872-168
Hank's buffer ~ 9.9 ~ 5.7
Iagredieats C D B
Pluronic L44 41.8 44.76 47.44 5
ole 1 alcohol 41.8 44.76 47.44 5
Hank's buffer 16.3 10.47 5.12
Iagredieata F RJ1TI0 d
Pluronic h44 19 2 34.2 4
ole 1 alcohol 75.9 8 51.3 6
Hank's buffer 5.1 9.4
Iagr~di~ats 8 t J
Pluronic F68 30 15 7.5
Haak's buffer 70 85 92.5
Iagrediaats Z 1t 1P'
Platonic F108 15 7.5 3.75
Hank's buffer 85 9.25 9.625
T11HL8 is
Microemulsions with Platonic L44 to Oily Phase Ratio of
3:7. Oily phases are either oleic acid or linoleic acid.
Percent aqueous phase (Hank's buffer) varies changes from
about lOt to about 14~.
Fos~ulation 1~
Pluronic'"L44 Z 7
oleic acid 63.1
Hank'e buffer ~ 9.9
Formulation 8
Platonic L44 Z~
_Z7_
m., .,ili.n.~..lw.~.i4.i.
CA 02185803 2004-12-O1
74872-168
linoleic acid 63.1
Hank' s buf f er ~ 9 . 9
Formulation C
Platonic L44 25.8
oleic acid 60.1 ~w
Aa~c s buf f er 14 .1
Foramlation D ~C
Pluronic~'L44 Z5.8
liaoleic acid 60.1
Hank s buf f er 14 .1
T118IS lZ
A) Platonic L44/iinoleic acid/Hank~s buffer aad B)
Platonic L44/oleic acid/Hasik's buffer microemulsioas at p8
6.5. The pH was increased using Na08 pellets.
Iagredients
PluronicTM L44 2 7
linoleic acid 63.1
Haak ~ buf f er 9 . 9
Na08 llets
pH 6.5
Iagredi~nta
PluroniC L44 27
oleic acid 63.1
Hanks buffer 9.9
NaOH pellets
8 6.5
-Z8-
i n . .., yw. . n li .n ..i-.l.y v . i F n i..
CA 02185803 2004-12-O1
74872-168
T118h8 14
Formulations of Pluronic I~44/linoleic acid/Aan)c's buffer
at various pH's. The pH was increased using Na0I3 pellets.
pDOOOS=sai
Fosmzulatioaa
PD000Z- '
Iagredieata 9D1 9DS 9D3
Pluronic L44 27 .27 Z7
linoleic acid 63.1 63.1 63.1
Hank' a buf f 9 . 9 9 . 9 9 . 9
er
8 3.5 4.5-5.0 6.0-6.5 '
PD000Z~9DZs Same Ae D1, but p8 ~4.5-5.0
pD000Z-9D3s Same As D1, but p8 6.0-6.5
PD000Z-9=1
Formulatioaa
PD000Z-
Iagredieata 9E1 9sZ ~ 9i3
Pluronic L44 27 27 Z7
oleic acid 63.1 63.1 63.1
Hank' s buf f 9 . 9 9 . 9 9'. 9
er
p8 3.5 4.5-5.0 6.0-6.5
PD000Z-9EZs Same Ae B1, but pH 4.5-5.0
pD000Z-9E3s Same AB B1, but p8 6.0-6.5
-a9-
i n "a.... .,~Iin.m4wr..i4.~.
CA 02185803 2004-12-O1
74872-168
TABI~ 15
Microemulsion component controls at various pH's: A)
Pluroaic L44 solutions at pH 2.2, 3.5, 4.8 and 7.9; H) Hank's
buffer at p8 2.1, 3.5, 5.0, 7.8; and C) linoleic acid.
Date
PD0002-l0A 5.4.94 26.8 Pluronic L44 in Hank's buffer
p8 7.9
PD0002-lOH 5.4.94 26.8 PluroniC'~L44 in Bank's buffer
p8 4.8
PD0002-10C 5.4.94 26.8 Pluronic'~L44 in Hank's buffer
8 3.5
PD0002-lOD 5.4.94 26.8 Pluronic~ L44 in Hank's buffer
p8 2.2
8
Date
PD0002-11A 5.4.94 100i~ HANR'S HDFFBR 8 7.8
PD0002-IlH 5.4.94 100 8AN1C'SHDFFBR 8 5.0
PD0002-11C 5.4.94 100 A74NR'SHDFFHR a a.l
PD0002-11D 5.4.94 100 HANK'S HDFP'BR8 3.5
C
Date
PD0002-lOB 5.4.94 1005 LINOLBIC ACID
-30-
.,. .~e.~....~H..-, w.~..
CA 02185803 2004-12-O1
74872-168
TA8L8 16
Pluroaic L44/linoleic acid/Hank's buffer microemulsion
at pH 3.5, 5.0 and 7Ø
PD000~-1~
Ingredieati 1~ H C
Pluronic""L44 ~ 27 26 . 8 25 . 5
linoleic acid 63.1 62.6 59.6
Hank's buffer 9.9 9.8 15
pH 3.5-3.8 4.9 9 '
Variations of the 8luroaic Z4~/Liaoleic ~lcid/Baak's
xicroaetulsioa Syatam
The following materials were used as received to prepare
the formulations : P7:uronic'" h44 (BASF, Parsippaay, N.T) ;
linoleic Acid (8mersol'~315, Henkel, emery Group, Cincinnati,
OH); oleic Acid IBmersol~" 221, Henkel, very Group ,
Cincinnati, OH); linolenic Acid (Aldrich, Milwaukee, WI);
Hank's Buffer ~(Cellgro. Mediatech); Bthaaol (Alcohol, -
dehydrated OSP, Midwest Grain Products of Illinois, Grain
Processing Corp., Muscarine, IA); and Tween'~ 20 (ICI
Surfactants, t6ilmington, D8) .
Ricinoleic acid (P-10 Acids, Cas Chem, Hayonne, NJ) was
centrifuged for 30 minutes at 15,000 rpm to remove solids.
The follorri.ag tables list the formulations prepared.
The tables give detailed information on the ingredients and
amounts and pH if appropriate.
-31-
CA 02185803 2004-12-O1
74872-168
The general procedure for preparing the microemulsions
is as follows: weigh ingredients into reclosable container,
shake and sonicate if necessary to remove bubbles.
Th8L8 19
Formulations for Pluroaic'"L44/oily phase/Haade buffer
microemulsions containing different fatty acids or alcohols
as the oily phase and partial substitution of Bands buffer
with ethanol.
For mulatio n: PDOOOa-
Iagredients 198 19F 20B 27A 27H 29A
(~) (~)~ (~) (~) (fir) (~)
Platonic I44 a7.0 Z7.0 27.fl 27.4 26.6 Z7
Aa,ak Buffer 9.9 9.9 9.9 8.8 9.9 4.95
'
oleyl
alcohol 63.1 0 0
oleic acid 0 63.1 63.1
liaoleic
acid 0 0 63.1 0 63.4 63.1
linoleaic
acid 0 63.4 63.1
ricinoleic
acid 0 63.4 63.1
ethanol 0 0 4.95
T7lHhi 11
Formulati~s for Platonic'" L44/fatty alcohol or
acid/Haak~s buffer containing oleyl alcohol, oleic acid or
liaoleic acid (PD0002-198, 19P, 208 respectively), with a
substitution of ethanol for part of the Bank's buffer,
(PD0002-31A, 31H and Z9A) and total substitution of Haal~c~s
buffer with ethanol (PD0002-31C) and a change in the ratio of
Platonic L44 to linoleic acid to 2:8 (PDOOOZ-31D).
-32-
I n . .m. . ..p II .n ...nlrN . i. I4 .I
CA 02185803 2004-12-O1
74872-168
Formulation PD0002-31
Ingredients A9 Hip C9 D9
Pluronic~L44 27 27 27 19
Hank's buffer 4.95 4.95 ~ N/A 5.1
oleyl alcohol 63.1 N/A N/A 75.9
oleic acid N/A 63.1 N/A N/A
liaoleic acid N/A N/A 63.1 N/A
ethanol 4.95 4.95 9.9 N/A
T718L~ 19
Formulations of Pluronic irt4/liaoleic acid/8ank's buffer
with varying substitutions of ethanol (PD0002-50A through J)
and Pluronic"" L44/oleyl alcohol/Baalc's buffer with ethanol
substitutions (PD0002-65).
Formulation PDOOOa-50
In edieats A B C D 8 F
Pluroaic L44 27 27 Z7 27 27 27
Hank's buffer 9.9 4.95 9.9 9.9 9.9 9.9
linoleic acid 63.1 63.1 54.1 58.6 49.6 45.1
ethanol 0 4.95 9 4.5 13.5 IB.02
For<aulation PD0002-50
In edieats G H I J
Pluroaic h44 27 27 27 27
Aaalc ~ s buf f 9 . 9 . 9 . 9 .
er 9 9 9 9
linoleic acid 40.54 36 31.5 Z'1
ethanol 22.52 27 31.5 36
-33-
CA 02185803 2004-12-O1
74872-168
Formulation PD0002-65
In redients A
'Pluronit~'L44 ~ Z7.03
Hank' s buf f er 9 . 91
oleyl alcohol 54.04
ethanol 9.01
T118hE Z 0
Addition of water soluble surfactaats SLS, sodium
cholate and Zl~reei~" ZO (PD000Z-3Z A, H, and C, respectively)
and addition of an oil soluble additive Eastman SAIH (PDOOOZ
. 34H) to miCroemulsion.
Formulation PD0002
In redients 3Z A~ 3Z Hip 3Z C~ 34 H~
Pluronic'~ i~44 Z 7 Z 7 2 7 Z 7
Hank's buffer 9.9 9.9 9.9 9.9
linoleic acid 63 63 63 63
Solium Lauzyl
Sulfate 0.1 N/A N/A N/A
sodium cholate N/A 0.1 N/A N/A
Tween ZO N/A N/A 0.1 N/A
8astmaa SAIH 0.111
-34-
CA 02185803 2004-12-O1
74872-168
Formulation Ingredients
PD0002-30 Pluronit'" ~ Pluronic~"~ Haak's
buf f er
A L3 5 0 . 5 95
H L61 0 . 5 95 ,
C L62 0.5 95
D L64 0.5 95
B L35 1 ~ 90
F L61 1 90
G L62 1 90
8 L64 1 90
I L44/L61 0.25/0.25 95
J L44/L61 0.5/0.5 90
R L44 5 95
T~DI~ 91
Substitutions of Pluronic L44 with L64 aad L35 is the
microeiaulsion formulations .
Formulation PD0002-33
Ingredients A ~ H ~
Pluronic L64 27 N/A
Hank's buffer 9.9 . 9.9
linoleic acid 63.1 63.1
Pluronic L35 N/A
-35-
, . .. "".,.. . . ., a " ,., ,~,. . . , v . ~ .
CA 02185803 2004-12-O1
74872-168
T~ ZZ
TM
Pluronic L62/linoleic acid/Hank's buffer microemulsion.
Formulation PD0002-418
Ingredients
Pluronic L62 . 42.8
Hank's buffer 14.4
liaoleic acid 42.8
-36-
